Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Joy Behar Reveals GLP-1 Weight Loss: 'I Was Prediabetic' on The View - Featured image
GLP-1 Medications

Joy Behar Reveals GLP-1 Weight Loss: 'I Was Prediabetic' on The View

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·February 19, 2026·5 min read

On this page

  • Joy Behar's Candid GLP-1 Revelation
  • Sunny Hostin's Mounjaro Success Story
  • Hollywood's Embrace of Ozempic, Mounjaro, and GLP-1 Drugs
  • What Are GLP-1 Medications and How Do They Work?
  • Benefits for Prediabetes, Weight Loss, and Beyond
  • Safety Profile and Common Side Effects
  • Who Should Consider GLP-1 Therapy? Patient Guidance
  • Key Takeaways: What This Means for Patients
  • Conclusion: Actionable Insights from The View
  • Mechanism of Action
  • Ozempic vs. Mounjaro: Key Comparisons

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

On The View, Joy Behar opened up about her GLP-1 weight loss success, noting she was prediabetic before starting. Co-host Sunny Hostin shared gaining 40 lbs during COVID and using Mounjaro to improve her cholesterol from 200 to 140. These stories highlight Hollywood's trend toward Ozempic and similar drugs for real health gains.

Share

On this page

  • Joy Behar's Candid GLP-1 Revelation
  • Sunny Hostin's Mounjaro Success Story
  • Hollywood's Embrace of Ozempic, Mounjaro, and GLP-1 Drugs
  • What Are GLP-1 Medications and How Do They Work?
  • Benefits for Prediabetes, Weight Loss, and Beyond
  • Safety Profile and Common Side Effects
  • Who Should Consider GLP-1 Therapy? Patient Guidance
  • Key Takeaways: What This Means for Patients
  • Conclusion: Actionable Insights from The View
  • Mechanism of Action
  • Ozempic vs. Mounjaro: Key Comparisons

In a candid moment on ABC's The View, co-host Joy Behar revealed her personal experience with GLP-1 medications for weight loss, disclosing that she was prediabetic. This revelation ties into Hollywood's hottest trend: celebrities turning to drugs like Ozempic, Mounjaro, and other GLP-1 agonists for transformative health improvements. Behar's story, alongside those of her co-hosts, underscores the growing popularity of these therapies among high-profile figures seeking metabolic health benefits.

Joy Behar's Candid GLP-1 Revelation

Joy Behar didn't hold back during a lively discussion on the show. She joked, "We lost a ton of weight at this table," highlighting the collective weight loss experiences among the The View panel. Behar specifically shared that she was prediabetic, a condition affecting blood sugar regulation that often precedes type 2 diabetes. By using GLP-1 medications, she has achieved noticeable weight loss, aligning with the drugs' reputation for aiding those with prediabetes and obesity-related risks.

Prediabetes affects millions, characterized by elevated blood sugar levels that increase heart disease and diabetes risks. Behar's openness brings attention to how GLP-1 therapies, originally developed for diabetes management, are now widely used off-label for weight loss in prediabetic individuals.

Sunny Hostin's Mounjaro Success Story

Co-host Sunny Hostin provided even more specifics about her journey. "During COVID, I gained 40 lbs. All I did was eat... I love to cook, and I found out, I love to eat. And I was horrified about the fact that I would have to come out on air," she explained on a 2024 episode. To address this, Hostin turned to Mounjaro.

The results were striking: "I found that my cholesterol went up to 200 when I gained the extra weight. And I use Mounjaro and my cholesterol is 140 now," the former attorney continued. "I feel better, I think I look better, and that's what this is about for people." Hostin's experience illustrates Mounjaro's dual benefits in weight reduction and lipid profile improvement, common outcomes in clinical use.

Hollywood's Embrace of Ozempic, Mounjaro, and GLP-1 Drugs

The conversation on The View reflects a broader celebrity trend. Stars have publicly credited Ozempic (semaglutide) and Mounjaro (tirzepatide) for dramatic weight loss. These GLP-1 receptor agonists mimic hormones that regulate appetite and insulin, making them effective for sustained weight management. While some women on the panel, including Sunny Hostin, specifically used Mounjaro, the buzz around these drugs has made them synonymous with Hollywood's push for health and vitality.

What Are GLP-1 Medications and How Do They Work?

Mechanism of Action

GLP-1 (glucagon-like peptide-1) medications like Ozempic and Mounjaro work by activating GLP-1 receptors in the body. This leads to slowed gastric emptying, reduced appetite, and increased insulin secretion in response to meals. For prediabetic individuals like Joy Behar, they help stabilize blood sugar. Tirzepatide in Mounjaro also targets GIP receptors, enhancing its weight loss efficacy compared to semaglutide alone.

These effects explain Sunny Hostin's cholesterol drop from 200 to 140, as weight loss often correlates with improved lipid levels and reduced cardiovascular risk.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Ozempic vs. Mounjaro: Key Comparisons

  • Ozempic (semaglutide): Weekly injection, FDA-approved for type 2 diabetes and chronic weight management. Popular for steady, sustainable results.
  • Mounjaro (tirzepatide): Dual-action GLP-1/GIP agonist, showing superior weight loss in trials (up to 20-25% body weight reduction). Hostin's 40-lb loss aligns with such outcomes.

Both are self-administered via pen injector, with dosing starting low to minimize side effects.

Benefits for Prediabetes, Weight Loss, and Beyond

Stories like Behar's and Hostin's highlight GLP-1 drugs' role in addressing prediabetes—a state where fasting blood sugar is 100-125 mg/dL. By promoting weight loss, they lower diabetes progression risk by up to 50% in studies. Improved cholesterol, as seen with Hostin, reduces heart disease odds, a key concern for overweight individuals.

Additional perks include better energy, mood, and appearance, echoing Hostin's sentiment: "I feel better, I think I look better."

Safety Profile and Common Side Effects

GLP-1 medications are generally well-tolerated but can cause nausea, vomiting, diarrhea, and constipation, especially during initiation. Rare risks include pancreatitis or gallbladder issues. Patients like those on The View should monitor with regular check-ups. Tools like Shotlee can help track symptoms, side effects, or medication schedules for better adherence.

Contraindications include personal/family history of medullary thyroid carcinoma. Always consult a healthcare provider before starting.

Who Should Consider GLP-1 Therapy? Patient Guidance

Ideal candidates mirror Behar and Hostin: those with prediabetes, obesity (BMI ≥30), or weight-related comorbidities like high cholesterol. Discuss with your doctor if you:

  • Struggled with weight gain, like Hostin's 40 lbs during COVID.
  • Have prediabetes or elevated lipids.
  • Seek non-surgical weight loss options.

Lifestyle integration—diet, exercise—amplifies results. Compare to alternatives like phentermine (short-term) or bariatric surgery (invasive). GLP-1s offer a middle ground with proven long-term data.

Key Takeaways: What This Means for Patients

  • Joy Behar's GLP-1 use addressed her prediabetes, contributing to panel-wide weight loss.
  • Sunny Hostin lost significant weight with Mounjaro, dropping cholesterol from 200 to 140.
  • These celebrity stories spotlight GLP-1s' real-world impact on metabolic health.
  • Consult professionals; track progress for optimal outcomes.

Conclusion: Actionable Insights from The View

Joy Behar's revelation and Sunny Hostin's detailed Mounjaro success affirm GLP-1 medications' value for prediabetes, weight loss, and cholesterol management. Hollywood's trend validates their efficacy, but personalized medical advice is essential. If you're prediabetic or facing similar challenges, talk to your doctor about Ozempic, Mounjaro, or GLP-1 options to potentially transform your health like these stars.

Source Information

Originally published by RadarOnline.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: GLP-1 Weight Loss

All GLP-1 Weight Loss articles →
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Health

Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter

Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.

8 min read
Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss
Health

Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss

Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.

8 min read
GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?
Health & Wellness

GP's Verdict on GLP-1 Tablet Rollout: A Damp Squib?

A UK GP shares his observations on the limited uptake of new GLP-1 weight loss tablets, suggesting patient familiarity with injections and daily dosing challenges may be factors.

8 min read

More in GLP-1 Medications

Lost 9 Stone on Mounjaro: Loose Skin Sparks ElastiK Skin Business
GLP-1 Medications

Lost 9 Stone on Mounjaro: Loose Skin Sparks ElastiK Skin Business

Marc McKee dropped nine stone with Mounjaro, transforming his health but leaving him with loose skin that inspired a new business. ElastiK Skin targets GLP-1 weight loss side effects using peptides, hyaluronic acid, and LED therapy. Early users report better hydration and elasticity with consistent use.

5 min read
Ozempic Fuels Tapatío Hot Sauce Boom: L.A. Icon's Story
GLP-1 Medications

Ozempic Fuels Tapatío Hot Sauce Boom: L.A. Icon's Story

Ozempic isn't just transforming waistlines—it's igniting a surge in hot sauce sales like Tapatío's. As millions embrace GLP-1 drugs, cravings for bold flavors skyrocket, propelling L.A.'s iconic brand into national expansion under new owners Highlander Partners. This is the untold story of family legacy meeting metabolic health trends.

5 min read
Amazon Adds Same-Day Delivery for GLP-1 Drug Foundayo
GLP-1 Medications

Amazon Adds Same-Day Delivery for GLP-1 Drug Foundayo

Amazon is revolutionizing access to GLP-1 weight-loss drugs by launching same-day delivery for Foundayo through Amazon Pharmacy in nearly 3,000 cities. Patients can now order with a valid prescription, check real-time availability, and get medication home-delivered faster than traditional options. This move cuts treatment barriers from prescription to doorstep.

4 min read
Share this article
  1. Home
  2. Blog
  3. Joy Behar Reveals GLP-1 Weight Loss: 'I Was Prediabetic' on The View
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community